Clinical trials
Locally Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting locally advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 4,340 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT07555210Recruiting
Bone Density Changes During Cancer Immunotherapy
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
Nashville, TennesseeAges 18 years+ - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT07780240Recruiting
Understanding arm band pain after breast cancer surgery
This study looks at how common axillary web syndrome (a rope-like band in the armpit after breast cancer surgery) is, who gets it, and how it affects arm function. It aims to help doctors better predict and manage this condition.
Istanbul, BAGCILARAges 18–80 - NCT07543536RecruitingPhase 3
Megestrol Acetate for Fatigue in HER2+ Breast Cancer
This study tests whether a medication called megestrol acetate can help reduce severe tiredness and fatigue in people with advanced breast cancer who are receiving a targeted therapy called T-DXd (trastuzumab deruxtecan). Fatigue is a common side effect that can really impact quality of life.
Guangzhou, GuangdongAges 18–75 - NCT04768426RecruitingPhase 2
Watching DNA in blood while taking capecitabine after breast cancer
This trial checks how a blood test that looks for cancer DNA (ctDNA) changes during and after you take capecitabine after early triple-negative breast cancer. It aims to see whether these blood test results can help monitor the chance of the cancer coming back.
Stanford, CaliforniaAges 18 years+ - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT06930118RecruitingPhase 2
Study of 4 drugs for advanced colorectal cancer
This trial tests a combination of four drugs for people with advanced colorectal cancer who have already tried at least two other treatments. The goal is to see if this new mix can help shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Birmingham, AlabamaAges 18 years+ - NCT06679387RecruitingPhase 2
Memantine to prevent paclitaxel nerve damage in breast cancer
This trial tests whether the drug memantine can help prevent or reduce nerve pain and other side effects caused by the chemotherapy drug paclitaxel in breast cancer patients. If you are about to start weekly paclitaxel, this study may offer extra protection to your nerves.
CairoAges 18 years+ - NCT06518837RecruitingPhase 2
Tirzepatide for weight loss in early breast cancer
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Elizabeth, New JerseyAges 18 years+ - NCT07135960Recruiting
Breast motion study after surgery and radiation
This study uses a 3D scanner to measure how your breast moves after surgery and possibly radiation. The results may help doctors improve treatment planning for future patients.
PortsmouthAges 18 years+ - NCT07661927RecruitingPhase 2
Skipping hormone therapy for low-risk breast cancer
This trial tests whether women with very low-risk, early-stage breast cancer can safely skip hormone therapy after surgery. It is designed for women who are 60 or older and whose cancer shows no spread to lymph nodes and has favorable biology.
AngersAges 60 years+ - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT07702708Recruiting
AI predicts chemotherapy response in HR+/HER2- breast cancer
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
Fuzhou, FujianAges 18 years+ - NCT04690439Recruiting
Light therapy to treat breast cancer–related arm swelling
This trial studies whether a noninvasive light-based treatment (photobiomodulation) can reduce breast cancer–related lymphedema, which is swelling in the arm or chest area due to lymph fluid buildup. If you qualify, you’ll be asked to follow a set treatment and follow-up schedule to see if symptoms improve safely.
Hasselt, LimburgAges 18 years+ - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT05320588RecruitingPhase 1/Phase 2
Early test of a cancer treatment for advanced solid tumors
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
Austin, TexasAges 18 years+ - NCT05388149RecruitingPhase 2
Neratinib plus Kadcyla to treat leftover HER2 breast cancer
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Toronto, OntarioAges 18 years+ - NCT05466786Recruiting
Testing gene changes and DNA damage in HER2-low breast cancer
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
Guangzhou, GuangdongAges 18–70 - NCT05475678RecruitingPhase 2
Camrelizumab plus chemo before surgery for triple-negative breast cancer
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
Zhengzhou, HenanAges 18–70
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 4,340 recruiting locally advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced/Metastatic Breast Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Advanced or Metastatic Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.